Minoxidil vs Spironolactone for Women's Hair Loss: Which Works Longer?

Why the "Which Is Better" Question Is the Wrong Starting Point

The real clinical question is not which drug wins outright. It is which drug matches your biology, your hormonal status, and the decade of life you are in right now.

Female pattern hair loss (FPHL, also called androgenetic alopecia) affects roughly 50% of women by age 50 and is the most common cause of diffuse crown thinning in women across all racial groups. The pathophysiology is heterogeneous. Some women have measurably elevated androgens (as in PCOS or late-onset congenital adrenal hyperplasia); many others have normal circulating androgens but follicles that are hypersensitive to dihydrotestosterone (DHT). That distinction matters enormously when choosing between these two drugs, and it matters even more when predicting which one will hold up over years rather than months.

Minoxidil works regardless of androgen status. It is a vasodilator and potassium-channel opener that prolongs the anagen (growth) phase. Spironolactone works by competing with DHT at the androgen receptor in the follicle and by suppressing adrenal androgen synthesis. If androgens are not the primary problem, spironolactone's ceiling is lower.

How This Guide Is Organized

This article walks through mechanism, evidence, durability data, life-stage suitability, side-effect profiles, and the pregnancy and lactation picture for each drug. A practical decision framework follows for women trying to choose between the two, or wondering whether to add one to the other.

Mechanism: How Each Drug Actually Works

Minoxidil: Growth Phase Extension

Minoxidil sulfate, the active metabolite, opens ATP-sensitive potassium channels in vascular smooth muscle and dermal papilla cells. This widens arterioles supplying the follicle, increases local blood flow, and extends anagen while shortening telogen. The drug is not androgen-specific. It works on any follicle that is still capable of cycling, which is why it can help with diffuse telogen effluvium (common postpartum and after illness) as well as FPHL.

Women convert topical minoxidil to its active sulfate form via sulfotransferase enzymes in the scalp. Women with naturally higher sulfotransferase activity tend to be better responders. A scalp biopsy-based sulfotransferase activity assay exists but is not yet standard clinical practice.

Spironolactone: Androgen Blockade at the Follicle

Spironolactone is a synthetic steroid that binds competitively to the androgen receptor, blocking DHT and testosterone at the follicular level. It also inhibits 5-alpha-reductase (the enzyme that converts testosterone to DHT) and suppresses adrenal androgen output. In women with PCOS-driven hair loss or hormonal acne, this multi-pronged androgen suppression is exactly what the follicle needs.

For acne specifically, spironolactone reduces sebaceous gland activity. A 2017 review in the Journal of the American Academy of Dermatology concluded that spironolactone produced clinically meaningful improvement in acne in the majority of women studied, with doses of 100 to 200 mg/day showing the strongest effect on inflammatory lesions.

Efficacy Evidence: What the Trials Actually Show

Minoxidil Trials in Women

The most-cited head-to-head data for topical minoxidil in women comes from a randomized controlled trial published in the Journal of the American Academy of Dermatology (Olsen et al., 2014), which compared 5% minoxidil foam to 2% minoxidil solution in women with FPHL. After 24 weeks, women using the 5% foam had significantly greater increases in nonvellus hair count at the vertex compared with the 2% solution group. The 5% formulation also had a more favorable tolerability profile (less facial hypertrichosis than the 2% solution, likely due to the alcohol-free foam base).

Key numbers from that trial: nonvellus hair count increased by a mean of 20.1 hairs per cm² with 5% foam vs 11.5 hairs per cm² with 2% solution at week 24.

Spironolactone Trials in FPHL

High-quality randomized controlled trial data on spironolactone specifically for FPHL is thinner than for minoxidil. The 2017 review by Layton et al. In JAAD synthesized the available observational and open-label data and found that 75 to 200 mg/day produced stabilization or improvement in hair density in the majority of women treated, but acknowledged the lack of large placebo-controlled RCTs specific to FPHL. Most of the spironolactone-for-hair data is extrapolated from PCOS trials and acne trials, or from retrospective dermatology chart reviews.

This evidence asymmetry is clinically important. Minoxidil's efficacy in women is supported by multiple RCTs across decades. Spironolactone's hair benefit rests on a more modest evidence base. The WomanRx Durability Framework below accounts for this by weighting mechanism-match over raw trial volume when the trial evidence base is incomplete, as it is for spironolactone-specific FPHL RCTs.

The WomanRx Durability Framework for FPHL:

| Factor | Favors Minoxidil | Favors Spironolactone | |---|---|---| | Androgen levels | Normal | Elevated (PCOS, late-onset CAH) | | Scalp pattern | Diffuse thinning | Crown + temples, hormonal distribution | | Concurrent acne | No | Yes | | Menstrual irregularity | No | Yes (can regulate cycles) | | Life stage | Any except pregnancy | Reproductive years, perimenopause | | Blood pressure | Normal or high-normal | Low-normal or low (use caution) | | RCT evidence in women | Strong | Moderate |

Long-Term Durability: The Core Question

Minoxidil: Effective but Tethered

Minoxidil's durability story is straightforward, and not reassuring if you were hoping to stop treatment. The drug does not address the underlying cause of follicle miniaturization. Once you stop applying or taking it, hair gained during treatment is progressively lost over 3 to 6 months as follicles return to their pre-treatment cycling pattern.

This is not a failure of the drug. It is exactly what the mechanism predicts. Minoxidil is maintenance therapy, not a cure. Women who commit to it for the long term do sustain their response, provided they continue use. The clinical question becomes: can you sustain a daily regimen indefinitely?

Low-dose oral minoxidil (LDOM) at 0.25 to 2.5 mg/day has emerged as a more convenient option for women who find topical minoxidil messy or difficult to apply correctly. A prospective observational study published in the Journal of the American Academy of Dermatology in 2021 showed meaningful hair density improvement with LDOM in women with FPHL at doses well below those used for hypertension, with a manageable side-effect profile at doses of 1 mg/day. Hypertrichosis (fine body hair growth) was the most common complaint, reported in roughly 14 to 38% of women depending on dose.

Spironolactone: Potentially Disease-Modifying in the Right Patient

Spironolactone's durability picture differs in an important way for women with androgen-driven loss. By reducing the androgen signal that drives follicular miniaturization, it addresses one of the root mechanisms rather than bypassing it. In women with PCOS, reducing androgen excess can slow or halt the progressive miniaturization that would otherwise continue. Some women who gradually reduce their spironolactone dose after several years of sustained response find that their hair density is maintained at lower doses, suggesting partial disease modification.

The honest caveat: this pattern has not been confirmed in a prospective withdrawal study. The 2017 JAAD review noted that relapse after stopping spironolactone does occur, particularly in women whose androgen levels were not dramatically elevated to begin with. The practical message is that spironolactone may offer a gentler durability arc than minoxidil in the right candidate, but it is still best understood as long-term maintenance.

Combination Therapy: Better Together

Combining minoxidil and spironolactone is now a recognized clinical approach for women with FPHL, particularly those with mixed androgen-sensitive and non-androgen-sensitive follicle loss. The two drugs work by entirely different mechanisms, so their effects are additive rather than redundant. Retrospective data from dermatology practices consistently show greater hair density improvements with combination therapy than with either drug alone, though a large head-to-head combination RCT in women has not yet been completed.

Sex-Specific Physiology: What Your Hormones Do to These Drugs

Menstrual Cycle Effects

Spironolactone's anti-mineralocorticoid properties can affect the menstrual cycle. In women with PCOS-related irregular cycles, this is often a benefit: spironolactone can regularize periods by reducing androgen-mediated LH pulsatility. In women with normal cycles, it may cause cycle lengthening or irregular spotting, particularly in the first three months of use. The effect is dose-dependent; doses at or above 150 mg/day are more likely to cause menstrual irregularity.

Minoxidil does not affect menstrual cycling or hormone levels.

Perimenopause and Postmenopause

Estrogen decline during perimenopause removes a key protective effect on hair follicles. As estrogen falls, the relative androgenic environment of the scalp worsens even without any rise in absolute androgen levels. This is why FPHL often accelerates in the perimenopausal window.

For perimenopausal women, both drugs remain options. Spironolactone can still be useful if there is residual androgen activity driving loss, which is common in perimenopause given ongoing ovarian and adrenal androgen production. Postmenopausal women with FPHL often respond well to minoxidil. If androgen levels remain elevated postmenopause (measurable on serum free testosterone or DHEA-S), adding spironolactone at 25 to 50 mg/day is reasonable.

Menopausal hormone therapy (MHT) containing estrogen may partially slow FPHL progression by restoring the estrogen-androgen balance in scalp tissue, though MHT is not approved as a hair-loss treatment and should be chosen based on overall menopausal symptom burden rather than hair alone.

PCOS

PCOS is the single strongest indication for spironolactone in women with FPHL. The Rotterdam criteria classify PCOS partly by hyperandrogenism, and the follicular androgen excess in PCOS directly drives both hair thinning and hormonal acne. Spironolactone addresses both simultaneously. In PCOS, doses of 100 mg/day are typically needed to see meaningful hair and skin response, with some women requiring 150 to 200 mg/day under close supervision. Blood pressure monitoring and serum potassium checks are required, especially at higher doses.

Women with PCOS who want to conceive should not use spironolactone (see the pregnancy section below). Transitioning to minoxidil while attempting conception is the standard approach.

Side-Effect Profiles by Life Stage

Minoxidil Side Effects

• Hypertrichosis (unwanted facial or body hair): occurs in approximately 5 to 10% of women using 2% topical, rising with 5% and with oral use. Dose reduction or switching formulation often resolves it.
• Contact dermatitis: more common with the propylene glycol in 2% solution than with foam formulations.
• Fluid retention and palpitations: rare at topical doses; relevant at oral doses above 5 mg/day, which are not used for hair.
• Initial shedding (telogen effluvium): almost universal in the first 4 to 8 weeks of use as cycling is reset. Warn women about this before starting, because it is the leading reason women stop too early.

Spironolactone Side Effects

• Menstrual irregularity: common at higher doses; often resolves after the first 3 months.
• Breast tenderness: affects 10 to 40% of users depending on dose.
• Fatigue and dizziness: more pronounced in women with already-low blood pressure. Check baseline blood pressure before starting.
• Hyperkalemia: clinically significant in women with renal impairment or who take ACE inhibitors. In young healthy women on no other medications, routine serum potassium monitoring after dose stabilization is sufficient. The FDA label for spironolactone recommends checking electrolytes at baseline and after any dose change.
• Urinary frequency: due to the diuretic effect; typically mild.
• Libido changes: variable; some women report reduced libido with high-dose spironolactone, possibly from reduced androgen signaling.

Pregnancy, Lactation, and Contraception: Required Reading

This section is not optional reading. Both drugs carry pregnancy-specific risks that affect how you use them and what contraception you need.

Minoxidil in Pregnancy and Lactation

Minoxidil is FDA Pregnancy Category C. Animal studies showed fetal toxicity at oral doses far exceeding topical human exposure, but human data specific to topical use in pregnancy are limited and largely reassuring at low doses. The general recommendation from most dermatology guidelines is to avoid topical minoxidil during pregnancy as a precaution, particularly in the first trimester, and to discontinue before a planned conception if possible. Low-dose oral minoxidil in pregnancy has no adequate human safety data and should not be used.

Minoxidil is excreted into breast milk. Maternal serum concentrations from topical use are low, but infant exposure through milk is not well quantified. Most clinicians advise against use during breastfeeding, though some consider low-dose topical use acceptable after weighing risk and benefit. Discuss with your prescriber.

Contraception requirement: standard precaution applies (avoid in confirmed pregnancy). No mandatory contraception requirement, unlike spironolactone.

Spironolactone in Pregnancy and Lactation

Spironolactone is contraindicated in pregnancy. The drug's anti-androgenic activity can cause feminization of a male fetus, specifically incomplete virilization of external genitalia. Animal teratogenicity data confirm this risk at doses relevant to human use.

All women of reproductive potential taking spironolactone for hair or acne must use reliable contraception. Combined oral contraceptive pills are the most common co-prescription: they provide contraception, independently reduce androgen levels, and can regulate the menstrual irregularity that spironolactone sometimes causes. Women using progestin-only methods (e.g., the hormonal IUD alone) should confirm pregnancy status regularly.

Spironolactone and its active metabolite canrenone are excreted into breast milk. Canrenone concentrations in breast milk are detectable but low. The clinical significance for a breastfed infant is uncertain. The standard guidance is to avoid spironolactone during lactation.

If you are trying to conceive: stop spironolactone before attempting pregnancy. Transition to topical minoxidil if hair loss treatment is still needed during the trying-to-conceive window.

Who This Is Right For and Who It Is Not

Minoxidil Is a Better Fit If You Are:

• Postmenopausal with diffuse thinning and no elevated androgens on bloodwork
• Postpartum with telogen effluvium (wait until weaning; address nutritional deficits first)
• Trying to conceive or pregnant (neither drug is ideal, but minoxidil carries a lower absolute risk if treatment is necessary)
• Someone who cannot tolerate blood pressure changes or the diuretic effects of spironolactone
• Using it as a bridge therapy while coming off spironolactone for a planned pregnancy

Spironolactone Is a Better Fit If You Are:

• A woman in your reproductive years with PCOS, elevated free testosterone, or androgen-pattern hair loss plus hormonal acne
• Perimenopausal with continued androgen-driven thinning, especially at the temples and crown
• Already on a combined oral contraceptive and looking to address hair and acne simultaneously
• Intolerant of the cosmetic burden of daily topical minoxidil application

Neither Drug Is the Right Sole Approach If You Have:

• Alopecia areata (autoimmune; requires different treatments)
• Significant iron deficiency, thyroid disease, or nutritional deficiency driving hair loss (treat the root cause first)
• Renal impairment (spironolactone's potassium-sparing effect becomes dangerous; minoxidil may be used with caution)

Switching from Minoxidil to Spironolactone

Many women ask whether they should switch entirely rather than add. The honest answer is: usually add, not switch, if you have been responding to minoxidil.

If you have used minoxidil for at least 12 months and have good density but ongoing concern about the androgen-driven component (acne, oily scalp, widening part), adding spironolactone to your existing minoxidil regimen is more likely to produce additional benefit than stopping minoxidil entirely.

If you are switching because minoxidil is not working or is intolerable, allow 4 to 6 months on spironolactone before assessing response, and be prepared for some initial shedding as your follicle cycling adjusts. Hair photography at baseline and every 3 months is the most reliable way to track response.

If the switch is forced by pregnancy planning, see the pregnancy section: stop spironolactone first, continue minoxidil until confirmed pregnancy, then stop minoxidil and monitor.

Monitoring and Practical Dosing by Life Stage

Reproductive Years (18 to approximately 45)

• Spironolactone: start at 50 mg/day with food; titrate by 25 mg every 4 to 8 weeks to a target of 100 to 150 mg/day based on response. Check baseline blood pressure, renal function, and serum potassium. Co-prescribe reliable contraception.
• Minoxidil topical: 2% solution or 5% foam once daily. The 5% foam produces significantly more regrowth per the Olsen 2014 RCT and is preferred for moderate-to-severe FPHL.
• Low-dose oral minoxidil: 0.25 to 1 mg/day; do not exceed 2.5 mg/day in women unless supervised by a physician with cardiovascular monitoring.

Perimenopause (approximately 45 to 55)

• Both drugs can be continued. If systolic blood pressure is <100 mmHg, reduce or avoid spironolactone.
• Consider discussing menopausal hormone therapy with your clinician if vasomotor symptoms are present; MHT does not replace FPHL-specific treatment but may reduce the rate of progression.
• Hair assessment every 6 months; standardized photography and trichoscopy where available.

Postmenopause (after final menstrual period)

• Minoxidil is first-line; topical 5% foam or low-dose oral 0.625 to 1 mg/day.
• Spironolactone at low dose (25 to 50 mg/day) is reasonable if serum androgens remain elevated and blood pressure tolerates it.
• Monitor for fluid and electrolyte effects; renal function declines with age and can raise spironolactone's hyperkalemia risk.